Ropinirole Hydrochloride
NDC Package 68258-7162-3

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. Frequently Asked Questions

Package Information

This product is EXCLUDED from the official NDC directory because the listing data was inactivated by the FDA.

Ropinirole Hydrochloride is parkinson’s DiseaseRopinirole Hydrochloride Tablets are indicated for the treatment of the signs and symptoms of idiopathic Parkinson’s disease.The effectiveness of Ropinirole Hydrochloride Tablets were demonstrated in randomized, controlled trials in patients with early Parkinson’s disease who were not receiving concomitant L-dopa therapy as well as in patients with advanced disease on concomitant L-dopa (see CLINICAL PHARMACOLOGY: Clinical Trials).Restless Legs SyndromeRopinirole Hydrochloride Tablets are indicated for the treatment of moderate-to-severe primary Restless Legs Syndrome (RLS).Key diagnostic criteria for RLS are: an urge to move the legs usually accompanied or caused by uncomfortable and unpleasant leg sensations; symptoms begin or worsen during periods of rest or inactivity such as lying or sitting; symptoms are partially or totally relieved by movement such as walking or stretching at least as long as the activity continues; and symptoms are worse or occur only in the evening or night. Marketed by Dispensing Solutions, Inc., this product is identified by NDC 68258-7162 and is authorized under FDA application ANDA090429.

Identification & Billing

NDC Package Code
68258-7162-3
Package Description
30 TABLET, FILM COATED in 1 BOTTLE
Product Code
68258-7162
11-Digit Billing Format
68258716203
RxNorm Crosswalk

Clinical Specifications

Proprietary Name
Ropinirole Hydrochloride
Dosage Form
-
Usage Information
Parkinson’s DiseaseRopinirole Hydrochloride Tablets are indicated for the treatment of the signs and symptoms of idiopathic Parkinson’s disease.The effectiveness of Ropinirole Hydrochloride Tablets were demonstrated in randomized, controlled trials in patients with early Parkinson’s disease who were not receiving concomitant L-dopa therapy as well as in patients with advanced disease on concomitant L-dopa (see CLINICAL PHARMACOLOGY: Clinical Trials).Restless Legs SyndromeRopinirole Hydrochloride Tablets are indicated for the treatment of moderate-to-severe primary Restless Legs Syndrome (RLS).Key diagnostic criteria for RLS are: an urge to move the legs usually accompanied or caused by uncomfortable and unpleasant leg sensations; symptoms begin or worsen during periods of rest or inactivity such as lying or sitting; symptoms are partially or totally relieved by movement such as walking or stretching at least as long as the activity continues; and symptoms are worse or occur only in the evening or night. Difficulty falling asleep may frequently be associated with moderate-to-severe RLS.

Regulatory & Marketing

Labeler Name
Dispensing Solutions, Inc.
FDA Application #
ANDA090429
Marketing Category
ANDA - A product marketed under an approved Abbreviated New Drug Application.
Start Marketing Date
09-18-2009
Listing Expiration
12-31-2017
Exclude Flag
I
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 68258-7162-3 identifies a specific commercial package of 30 tablet, film coated in 1 bottle of Ropinirole Hydrochloride, labeled by Dispensing Solutions, Inc.. This is formulated for use and contains as the active substance.

Is this product currently listed with the FDA?

This product code is currently listed as inactive or excluded from the primary directory. It was introduced to the market by Dispensing Solutions, Inc. on September 18, 2009. The current certification is valid through December 31, 2017.

How is this Dispensing Solutions, Inc. product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 68258716203. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-4-1)
68258-7162-3
11-Digit CMS (5-4-2)
68258-7162-03

Note: The zero is added to the Package segment to maintain the 5-4-2 structure.